Emogin Tablet 50 mg (TM), also known as Ragwitek or Merck Brand name Tezepelumab, is a biological drug used to treat moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. It works by blocking chemicals that are involved in inflammation.
Emogin Tablet 50 mg is typically used to treat moderate to severe atopic dermatitis (eczema) in both adults and children aged 6 years and older. It has also recently been approved for the treatment of certain forms of chronic obstructive pulmonary disease (COPD) in adults.
| Brand Name | Emogin |
|---|---|
| Type | Tablet |
| Weight | 50 mg |
| Generic | Tiemonium Methylsulphate |
| Manufacturer | Somatec Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Emogin Tablet 50 mg works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the inflammation associated with atopic dermatitis. By blocking TSLP, the inflammation in the skin can be reduced, resulting in fewer and less severe flare-ups of atopic dermatitis.
The effects of Emogin Tablet 50 mg can be seen as soon as 1 week after starting treatment, although it may take up to 8 weeks to see full results.
Emogin Tablet 50 mg is administered as an injection under the skin (subcutaneously). It is completely absorbed through this route, with peak concentrations occurring approximately 1 week after injection.
Emogin Tablet 50 mg is eliminated through the kidneys, primarily as its active metabolite, desethyl tiemonium, which is excreted in urine.
The recommended dosage of Emogin Tablet 50 mg is 200 mg given as an injection beneath the skin (subcutaneously) every 4 weeks.
Emogin Tablet 50 mg should be administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. Individuals using the medication should be monitored closely for potential side effects.
Common side effects of Emogin Tablet 50 mg may include:
There are no reports of toxicity associated with Emogin Tablet 50 mg use, however it can cause serious side effects in certain individuals.
Emogin Tablet 50 mg may interact with other medications, herbs, or supplements that may also affect the skin, including retinoids, calcitriol, and tacrolimus.
Emogin Tablet 50 mg should be used with caution in patients with severe kidney disease, cirrhosis of the liver, or HIV/AIDS.
Emogin Tablet 50 mg may interact with certain drugs, including antiepileptic drugs, immunosuppressants, and other drugs that are used to treat atopic dermatitis. Patients should consult with their healthcare provider before taking Emogin Tablet 50 mg alongside any other medications.
Food interactions with Emogin Tablet 50 mg are not known.
It is not known if Emogin Tablet 50 mg is excreted in breastmilk. Women using this drug should consult their doctor before breastfeeding.
The effects of an acute overdose are not known. Seek medical attention immediately if an overdose is suspected.
Emogin Tablet 50 mg is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also not be used in combination with certain medications, including retinoids, calcitriol, and tacrolimus.
Emogin Tablet 50 mg is administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. The recommended dose is 200 mg every 4 weeks.
Emogin Tablet 50 mg should be stored at 2°C to 8°C (36°F to 46°F).
The volume of distribution of Emogin Tablet 50 mg is not known.
The half-life of Emogin Tablet 50 mg is approximately 22 days.
The clearance of Emogin Tablet 50 mg is not known.
See in details version Emogin Tablet 50 mg also Emogin Tablet 50 mg in bangla